Methamphetamine psychosis, the efficacy of atypical antipsychotics

Publish Year: 1394
نوع سند: مقاله ژورنالی
زبان: English
View: 319

This Paper With 6 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_RCM-2-1_003

تاریخ نمایه سازی: 2 دی 1398

Abstract:

Worldwide growing methamphetamine abuse is one of the most serious health problems with several different consequences for victims, especially in developing countries. Chronic methamphetamine abuse is associated with several psychiatric problems in all countries which are faced to epidemic methamphetamine abuse. Methamphetamine-induced psychosis is a major medical challenge for clinical practitioner from both diagnostic and therapeutic viewpoints. Stimulant psychosis commonly occurs in people who abuse stimulants, but it also occurs in some patients taking therapeutic doses of stimulant drugs under medical supervision. The main characteristic of meth psychosis is the presence of prominent hallucinations and delusions. Other drugs, such as cocaine and marijuana, can trigger the onset of psychosis in someone who is already at increased risk because they have vulnerability .The current literature review attends to explain several aspects of MIP epidemiologically and clinically. Investigators proposed pharmacologically treatment based on recently published data.

Authors

Amir Rezaei Ardani

Psychiatry & Behavioral Sciences Research Center, Ibn-e-Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Azam Motamedi Nasab

Psychiatry & Behavioral Sciences Research Center, Ibn-e-Sina Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • WHO Technical Briefs 2011. Patterns and consequences of the use ...
  • United Nations Office on Drugs and Crime (UNODC). 2012. World ...
  • SAMHSA [Substance Abuse and Mental Health Services Administration] OoASTEDST, National ...
  • Batki SL, Harris DS. Quantitative drug levels in stimulant psychosis: ...
  • Chen C-K, Lin S-K, Sham P, et al. Pre-morbid characteristics ...
  • McKetin R, McLaren J, Lubman DI, et al. The prevalence ...
  • Caton CL, Drake RE, Hasin DS, et al. Differences between ...
  • Grant KM, LeVan TD, Wells SM, et al. Methamphetamine-associated psychosis. ...
  • Fasihpour B, Molavi S, Shariat SV. Clinical features of inpatients ...
  • Ujike H, Sato  M. Clinical features of sensitization to methamphetamine ...
  • McKetin R, Lubman DI, Baker AL, et al. Dose-related psychotic ...
  • Chen CK, Lin SK, Sham PC, et al. Morbid risk ...
  • Christian DR, Huber A, Brecht ML, et al. Methamphetamine users ...
  • Salo R, Nordahl TE, Leamon MH, et al. Preliminary evidence ...
  • Teraoka A. A study on methamphetamine psychosis in a psychiatric ...
  • Mahoney JJ 3rd, Hawkins RY, De La Garza R 2nd, ...
  • Akiyama K. Longitudinal Clinical Course Following Pharmacological Treatment of Methamphetamine ...
  • Srisurapanont M, Ali R, Marsden J, et al. Psychotic symptoms ...
  • Matsumoto T, Kamijo A, Miyakawa T, et al. Methamphetamine in ...
  • Nakama H, Chang L, Cloak C, et al. Association between ...
  • Zweben JE, Cohen JB, Christian D, et al. Psychiatric symptoms ...
  • Fujii D. Risk factors for treatment-resistive methamphetamine psychosis. J Neuropsychiatry ...
  • Sato M. A lasting vulnerability to psychosis in patients with ...
  • Yui K, Ikemoto S, Ishiguro T, et al. Studies of ...
  • McElhiney MC, Rabkin JG, Rabkin R, et al. Provigil (modafinil) ...
  • Turner DC, Clark L, Dowson J, et al. Modafinil improves ...
  • Turner DC, Clark L, Pomarol-Clotet E, et al. Modafinil improves ...
  • Newton TF, Roache JD, De La Garza R, et al. ...
  • Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for ...
  • Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled ...
  • Tiihonen J, Kuoppasalmi K, Föhr J, et al. A comparison ...
  • Klee SW, Tom Carnwath, John Merrill, Hilary. The role of ...
  • Shearer J, Wodak A, Mattick RP, et al. Pilot randomized ...
  • Longo M, Wickes W, Smout M, et al. Randomized controlled ...
  • Sulaiman AH, Gill JS, Said MA, et al. A randomized, ...
  • Farnia V, Shakeri J, Tatari F, et al. Randomized controlled ...
  • Oshibuchi H, Inada K, Ishigooka J. Action of amygdala dopamine ...
  • Futamura T, Akiyama S, Sugino H, et al. Aripiprazole attenuates ...
  • Meredith CW, Jaffe C, Yanasak E, et al. An open-label ...
  • Misra L, Kofoed L. Risperidone treatment of methamphetamine psychosis. Am ...
  • Iyo M, Sekine Y, Matsunaga T, et al. Methamphetamine-associated obsessional ...
  • Hatzipetros T, Raudensky JG, Soghomonian JJ, et al. Haloperidol treatment ...
  • Mauri MC, Volonteri LS, Fiorentini A, et al. Two weeks’ ...
  • Misra LK, Kofoed L, Oesterheld JR, et al. Olanzapine treatment ...
  • Heinzerling KG, Shoptaw S, Peck JA, et al. Randomized, placebo-controlled ...
  • Urschel III HC, Hanselka LL, Gromov I, et al.  Open-label ...
  • Fechtner RD, Khouri AS, Figueroa E, et al. Short-term treatment ...
  • Brodie JD, Figueroa E, Laska EM, et al. Safety and ...
  • Johnson BA, Roache JD, Ait-Daoud N, et al. Effects of ...
  • Dewey SL, Morgan AE, Ashby CR, et al. A novel ...
  • Cousins MS, Roberts DC, de Wit H. GABA(B) receptor agonists ...
  • De La Garza R 2nd, Zorick T, Heinzerling KG, et ...
  • Ito K. The role of gamma-aminobutyric acid (GABA)-benzodiazepine neurotransmission in ...
  • Kaneko Y, Kashiwa A, Ito T, et al. Selective serotonin ...
  • Ago Y, Nakamura S, Baba A, et al. Neuropsychotoxicity of ...
  • Chiu CT, Ma T, Ho IK. Attenuation of methamphetamine-induced behavioral ...
  • Anggadiredja K, Sakimura K, Hiranita T, et al. Naltrexone attenuates ...
  • Jayaram-Lindström N, Wennberg P, Hurd YL, et al. Effects of ...
  • Jayaram-Lindström N, Wennberg P, Beck O, et al. An open ...
  • Jayaram-Lindström N, Konstenius M, Eksborg S, et al. Naltrexone attenuates ...
  • Jayaram-Lindström N, Hammarberg A, Beck O, et al. Naltrexone for ...
  • Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study ...
  • Tanibuchi Y, Shimagami M, Fukami G, et al. A case ...
  • Hashimoto K. Minocycline as a therapeutic drug for methamphetamine use ...
  • Grelotti DJ, Kanayama G, Pope HG. Remission of persistent methamphetamine-induced ...
  • نمایش کامل مراجع